Intercept Pharmaceuticals
acquired by Alfasigma4 known investors
Find your way into Intercept Pharmaceuticals
Sign up to see every warm intro you have to Intercept Pharmaceuticals
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Intercept Pharmaceuticals team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Intercept Pharmaceuticals develops and commercializes treatments for rare and serious liver and other diseases, with a focus on conditions such as primary biliary cholangitis. The page displays corporate news related to Alfasigma, its parent/affiliated pharmaceutical company.
Investors · 4
Founder mafia
The Intercept Pharmaceuticals mafia →6 people who came through Intercept Pharmaceuticals went on to found or lead other companies.
Daniel BradburyDirectorFounded SensulinPaul SekhriBoard DirectorFounded VtvtherapeuticsRachel McMinnChief Business and Strategy OfficerFounded NeurogeneSenthil SundaramHead of Business/Corporate DevelopmentFounded Terns PharmaceuticalsAlex MartinCOOFounded AbcuroMike YoungConsultant, Organizational Development & PlanningFounded Comanche Biopharma
Frequently asked questions
- What does Intercept Pharmaceuticals do?
- Intercept Pharmaceuticals develops and commercializes treatments for rare and serious liver and other diseases, with a focus on conditions such as primary biliary cholangitis. The page displays corporate news related to Alfasigma, its parent/affiliated pharmaceutical company.
- Who are Intercept Pharmaceuticals's investors?
- Intercept Pharmaceuticals's investors include Aisling Capital, BioBrit, Ridgeback Capital, Samsara BioCapital.
- Who acquired Intercept Pharmaceuticals?
- Intercept Pharmaceuticals was acquired by Alfasigma.






